Description
Product Usage Information
Western Blotting: 1:1000
Immunohistochemistry (Paraffin): 1:125 - 1:500
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 59679 .
Protocol
Available protocols: Western Blotting, Immunohistochemistry (Paraffin)
Specificity / Sensitivity
SLC40A1/Ferroportin-1 (F9U5S) Rabbit Monoclonal Antibody recognizes endogenous levels of total SLC40A1/Ferroportin-1 protein. Non-specific staining was observed in pancreatic acinar cells by immunohistochemistry. This antibody is not recommended for immunohistochemical analysis of mouse tissues.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu265 of human SLC40A1/Ferroportin-1 protein.
Background
Ferroportin-1 (FPN1), also known as solute carrier family 40 member 1 (SLC40A1) or iron-regulated transporter 1 (IREG1), is a multi-pass membrane protein that transports iron from the inside of the cell into the blood. As the only known iron exporter, FPN1 is critical for maintaining systemic iron homeostasis (1). FPN1 activity is regulated by hepcidin, a peptide hormone secreted by the liver in response to iron loading and inflammation. Circulating hepcidin binds to FPN1 and induces its internalization and degradation, thereby reducing iron efflux to the plasma (2,3). Expression of FPN1 may also be regulated post-transcriptionally by several microRNAs that directly target its 3' untranslated region (4-6). Mutations in the gene encoding FPN1 are associated with type IV hemochromatosis (7) as well as several neural tube and patterning defects, including spina bifida, exencephaly, and forebrain truncations (8). Loss of FPN1 in the brains of Alzheimer's disease (AD) mouse models and patients has been shown to promote ferroptosis, leading to neuronal death and memory impairment. Therefore, targeting of FPN1 may be a promising therapeutic approach for AD (9).
Alternate Names
ferroportin 1; Ferroportin-1; FPN1; HFE4; IREG1; iron regulated gene 1; Iron-regulated transporter 1; MST079; MSTP079; MTP1; putative ferroportin 1 variant IIIB; S40A1; SLC11A3; SLC40A1; solute carrier family 11 (proton-coupled divalent metal ion transporters), member 3; solute carrier family 40 (iron-regulated transporter), member 1; Solute carrier family 40 member 1
